Issue

Vol. 66 No. 3: Issue 3

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization

https://doi.org/10.14715/cmb/2020.66.3.7
Yongpin Chen
Department of emergency, Xinglin branch of the first affiliated hospital of Xiamen university, Xiamen, Zhejiang361021, China
Weibin Li
Department of general surgery, Qianwei hospital of Jilin Province, Changchun, Jilin 130012, China
Qing Yang
Department of blood transfusion, the second department of the first hospital of Jilin university, Changchun, Jilin 130021, China.
Liang Chen
Changjiang Zeng

Corresponding Author(s) : Changjiang Zeng

chuandongyu163@gmail.com

Cellular and Molecular Biology, Vol. 66 No. 3: Issue 3

Abstract

Alpha-fetoprotein (AFP) is a protein encoded by the AFP gene and normally produced by the fetus. The purpose of this study is to investigate the efficacy of lobaplatin in combination with 5-fluorouracil (5-FU) and doxorubicin on AFP and treatment of primary carcinoma of the liver by transhepatic arterial chemotherapy and embolization (TACE). Patients with primary carcinoma of the liver who took the TACE for treatment were enrolled in this study and divided randomly into the research group and the control group. Patients in the research group adopted the TACE in combination with lobaplatin, while those in the control group took cisplatin instead in combination with TACE. We compared the baseline data, hepatic indicators before treatment and after 1 month of treatment, efficacy and the incidence rates of adverse events after TACE between two groups. Differences in the baseline data, including Child-pugh grade, type of liver cirrhosis, KPS scores and AFP showed no statistical significance (P >0.05). Before the treatment, we identified no significant differences in the comparison of ALT, AST, TBiL and ALB between two groups (P >0.05), while significant differences emerged after treatment (P <0.05). Also, efficacy comparison revealed the significant difference between the two groups (P <0.05). After TACE, patients in the research group reported 1 case of nausea, 1 of vomiting and 1 of necrotic absorption fever, and those in the control group reported 3 cases of nausea, 5 of vomiting and 4 of necrotic absorption fever, with a significant difference in comparison of the incidence rates (P <0.05). TACE is a promising strategy for the treatment of primary carcinoma of the liver, while lobaplatin, as the 3rd generation of anti-tumor platinum-based drugs, is less toxic than cisplatin, but excels in efficacy.

Keywords

Lobaplatin TACE Liver cancer Clinical efficacy.
Chen, Y., Li, W., Yang, Q., Chen, L., & Zeng, C. (2020). Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization. Cellular and Molecular Biology, 66(3), 48–51. https://doi.org/10.14715/cmb/2020.66.3.7
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Koh YH, Lee WJ, Park SJ, et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat. 2015; 47: 34–45.
  2. Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol. 2014; 20:16630–16638.
  3. Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev. 2015; 81:62–74.
  4. Yu JI, Park HC. Considerations for radiation therapy in hepatocellular carcinoma: the radiation oncologists' perspective. Dig Dis. 2014; 32:755–763.
  5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138:513–521.
  6. Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR III. Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States. J Hepatol. 2012; 56:618–625.
  7. Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol. 2013; 24:307–315.
  8. Onishi H, Nouso K, Nakamura S, Katsui K, Wada N, Morimoto Y, Miyahara K, Takeuchi Y, Kuwaki K, Yasunaka T, et al. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol Int. 2015; 9:105–112.
  9. Dai W, Wang F, Lu J, Xia Y, He L, Chen K, Li J, Li S, Liu T, Zheng Y, et al. By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. Oncotarget. 2015; 6:13703–13717.
  10. Kwan SW, Fidelman N, Ma E, Kerlan RK, Jr, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012; 18:727–736.
  11. Sherman M, Bruix J, Porayko M, Tran T, for AASLD Practice Guidelines Committee Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012; 56:793–796.
  12. Ozhathil DK, Li YF, Smith JK, Tseng JF, Saidi RF, Bozorgzadeh A, Shah SA. Impact of center volume on outcomes of increased-risk liver transplants. Liver Transpl. 2011; 17:1191–1199.
  13. Han H, Li W, Shen H, Zhang J, Zhu Y, Li Y. microRNA-129-5p, a c-Myc negative target, affects hepatocellular carcinoma progression by blocking the Warburg effect. J Mol Cell Biol. 2016; 8:400–10.
  14. Xu D, Jin J, Yu H, Zhao Z, Ma D, Zhang C, Jiang H. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. J Exp Clin Cancer Res. 2017; 36:44.
  15. Kazemi E, Kahrizi D. The repeatability of PCR-RFLP method for study of association between gastric cancer and manganese superoxide dismutase mutant (Val-9Ala). Biharean Biol 2017; 11(2), 112-114.
  16. Kazemi E, Kahrizi D. Lack of association between gastric cancer and hopq alleles in Helicobacter pylori. Genetika 2016; 48(3): 893-902
  17. Kazemi E, Kahrizi D, Moradi MT, Sohrabi M, Yari K. Gastric Cancer and Helicobacter pylori: Impact of hopQII Gene. Cell Mol Biol 2016; 62(2): 107-110.
  18. Kazemi E, Kahrizi D, Moradi MT, Sohrabi M, Amini A, Mousavi SAR, Yari K. Association between Helicobacter pylori hopQI genotyping and human gastric cancer. Cell Mol Biol 2016; 62(1): 6-9.
  19. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Modern Genetics J 2020; 15(2): 75-92.
  20. Kazemi E, Kahrizi D, Moradi MT, Sorabi, M, Amini S, Mousavi S.A.R., Yari K. Association between Manganese Superoxide Dismutase (MnSOD Val-9Ala) genotypes with the risk of generalized aggressive periodontitis disease. Cell Mol Biol 2016; 61 (8): 49-52.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 794 Download : 455